Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor

Abstract

AbstractIntroductionThe safety and efficacy of sodium glucose cotransport‐2 inhibitors (SGLT2i) in kidney transplant recipients remains uncertain. Transplant recipients may be at risk of thrombosis because of post‐transplant erythrocytosis and SGLT2i are associated with an increase in hematocrit.MethodsWe determined SGLT2i use, the change in hematocrit and incidence of thrombotic events in kidney transplant recipients in 1700 prevalent patients in our center.ResultsAmong the 42 patients treated with SGLT2i, the mean pre‐transplant hematocrit was 31%, and none of the patients had a hematocrit ≥50%. The mean percent change in hematocrit measured at an average of 53 days after initiation of an SGLT2i was 11% and four patients (10%) had a hematocrit ≥ 50%. The mean hematocrit measured 3 months after treatment was 42% and two patients (5%) had a hematocrit ≥50%. One patient had a cerebellar stroke 14 months post‐SGLT2i initiation when the hemoglobin was 173 grams/liter, and the hematocrit was 52%.ConclusionsAll patients had a sustained increase in hematocrit 3 months after SGLT2i treatment. Hematocrit ≥50% occurred in 10%, and one patient had a thrombotic event that may or may not have been related to an increase in hematocrit. Clinicians may consider monitoring for erythrocytosis after starting and SGLT2i in kidney transplant recipients.